Search for: "In re: Effexor XR Antitrust v."
Results 1 - 5
of 5
Sorted by Relevance
|
Sort by Date
16 Aug 2013, 9:57 am
The FTC’s amicus brief states that the Effexor XR case presents “an issue with significant implications for American consumers”: whether pharmaceutical patent settlements are “immune from antitrust scrutiny so long as the brand-name drug manufacturer pays for delayed entry with something other than cash. [read post]
16 Aug 2013, 9:57 am
The FTC’s amicus brief states that the Effexor XR case presents “an issue with significant implications for American consumers”: whether pharmaceutical patent settlements are “immune from antitrust scrutiny so long... [read post]
27 Aug 2017, 10:01 pm
Supp. 3d 523 (D.N.J. 2014); In re Effexor XR Antitrust Litig., No. [read post]
27 Aug 2017, 10:01 pm
Supp. 3d 523 (D.N.J. 2014); In re Effexor XR Antitrust Litig., No. [read post]
29 Aug 2012, 10:09 pm
EFFEXOR XR. [read post]
